A subsequent study, the CVD REAL 2 study, found that use of SGLT2 inhibitors (versus other glucose-lowering drugs) in patients with T2D from Asia, the Middle East and North America was associated with a lower risk of all-cause death, hospitalization for HF, MI and stroke [55]. The gene discussed is SLC5A2; the disease is hydrops fetalis.